Podcast appearances and mentions of andy southerland

In part two of this series, Dr. Andy Southerland and Dr. Dan Ackerman discuss a few rapid‑fire concepts from the 2026 guidelines, focusing on what is new and how emerging data may shape patient care.  Show transcript:  Dr. Andy Southerland: Hello, everyone. This is Andy Southerland from the University of Virginia. And for today's Neurology Minute, I'm speaking with my friend and colleague, Dan Ackerman, Chief of Neurology and Director of Stroke at St. Luke's University Health System. We've been speaking in the main neurology podcast on tips for updated clinical practice related to the 2026 American Heart Association guidelines for the early management of patients with acute ischemic stroke. I'm going to hit Dan with a few rapid fire concepts that were touched on the guidelines that I think are new or provide some new insights, new based on the data and to how we treat patients. So Dan, you ready for it? Rapid fire, acute stroke treatment decision making? Dr. Dan Ackerman: Absolutely. Hit me. Dr. Andy Southerland: All right, Dan. I'm a resident going to my first stroke alert on July one this year and I've got a patient coming in, they're having disabling stroke symptoms and they're, in every other way, eligible to receive thrombolysis, but they have a history of paroxysmal atrial fibrillation. They are on apixaban and they took a dose of that apixaban. They forgot to take one yesterday, but they took one the day before, had the evening before. And so 36 hours ago, they took a dose of their apixaban. So based on previous dogma, I think prior guidelines might've said if it's within that 48 hour window, that's a relative contraindication of thrombolysis. What, say, you based on the new guidelines and then how do they inform us about making that decision? Dr. Dan Ackerman: I would actually say the new guidelines are a little bit more aligned with what you just said. You mentioned it as a relative contraindication to thrombolysis. I think before these guidelines came out, a lot of people would've said, "No, that is a strict contraindication to thrombolysis." And a lot of folks would run a stroke code or a stroke lid a little slower knowing that, hey, this person is on, whether it's apixaban, rivaroxaban, edoxaban, dabigatran, et cetera, any of these direct oral anticoagulants and say, "Well, no, we know that person's not a candidate for thrombolytics." Well, no, the newer guidelines would suggest that that is a relative contraindication, not a strict contraindication. And when we look back at studies on this, it has not been suggested that there is a big contribution in terms of exactly how long ago that last dose was. Was it two hours ago, 12 hours ago, 20 hours ago? And there has not been shown to be a clear benefit of testing for factor Xa activity levels, bleeding time and the like. So the guidelines do suggest that, hey, we need more data on this. It's not to, say, that this is 100% perfectly fine. Remember, that's a relative contraindication, so it's still a risk benefit discussion, but studies have not shown an increased risk for hemorrhagic complications in patients who have had recent DOAC exposure who receive IV thrombolysis otherwise according to the guidelines. So I would tend to offer it in that situation and make sure that we document what drugs someone's on, how long ago was their last dose, all of this kind of information in addition to what we might normally otherwise get down. Dr. Andy Southerland: Does that change, Dan, if they took the DOAC in the last 24 hours or even 12 hours? They took it last night, and they're presenting in the morning with their stroke-like symptoms? Dr. Dan Ackerman: The guideline just suggests less than 48 hours, and the data, to my knowledge, doesn't really delineate, at this point, any particular timeframe where we would say, no, there's a cutoff there at two hours or eight hours or 12 hours. So at this point, I would not use that as a way to decide not to offer thrombolysis based on that timeframe. Dr. Andy Southerland: Fair enough. I think that's very reasonable. And I think, again, it's always a good conversation to have either with your attending, if you're that resident on July 1, but particularly with the patient and their family on the risk-benefit of what we know based on the data. Well, that's all the time we have for this Neurology Minute. We hope this discussion will continue to help everyone out there in the hyperacute management of patients with acute ischemic stroke, making those difficult treatment decisions. Good luck.  

In part two of this series, Dr. Andy Southerland talks with Dr. Dan Ackerman about a few rapid‑fire concepts from the 2026 guidelines, focusing on what is new and how emerging data may shape patient care. Disclosures can be found at Neurology.org.

In part one of this series, Dr. Andy Southerland and Dr. Dan Ackerman discuss what stands out in the latest thrombolysis guidelines, how these decisions are applied in stroke center practice, and how to educate residents and fellows on incorporating new evidence into treatment choices. Show transcript: Dr. Andy Southerland: Hi. This is Andy Southerland from the University of Virginia, and for today's Neurology Minute, I'm speaking with my friend and colleague, Dan Ackerman, Chief of Neurology and Director of Stroke at St. Luke's University Health System. I've been speaking with Dan on the main neurology podcast regarding updates to acute stroke treatment related to the 2026 American Heart Association guidelines that came out in late January of this year on the early management of patients with acute ischemic stroke. For our episode today, we might focus our discussion around thrombolytic therapy thrombolysis, which is at the core of what we do as acute stroke neurologists when it comes to treatment decision-making. So maybe as a first prompt, Dan, when you look at these guidelines, what stands out to you as you're thinking about how you practice, how you all are practicing at your stroke center, and then specifically how we educate our residents, our fellows on what they need to know, particularly the newness of it when it comes to making thrombolysis treatment decisions? Dr. Dan Ackerman: With all the discussions we've had in the past, there have been a lot of specifics about certain studies and how they might affect practice, but this guideline really opened up a lot and gave us an opportunity to do things in a way that makes really good clinical sense and really brings a lot of practices that have now become common at some centers into the fore so that we can get that information out to everyone and make sure everyone has that same really high level of stroke care everywhere they go. I think the first thing that stands out to me is what did not change. And want to reinforce that, particularly for people who are just getting into this, stroke alert is a screening tool, not a severity score. It's not like an MI alert where you do an EKG and you see the tombstone wave and you say, "Oh, there's an MI and we're taking them to treatment." This is a screening tool, so it is meant to be highly sensitive at the cost of being specific. At our shop for a long time now, we have initiated stroke alert for anyone who presents either within 24 hours of acute onset of neurologic symptoms or has an unknown onset of acute neurologic symptoms and they are still symptomatic to some degree at the time of their presentation, and that's it. We don't make any other statements about how severe something is or what kinds of symptoms someone necessarily has to have. We purposely keep it as broad as possible, again, because we're trying to screen. And the other thing that has not changed, time is still brain. So with all of these different nuances on how we can treat patients and who might be candidates for intervention, it is still a matter of understanding these guidelines, applying our best evidence, but doing it as quickly as possible to make sure that we are rescuing as much of that ischemic penumbra as we possibly can. Now, aside from that, in terms of what stands out that is different, I think one of the early things for me are the recommendations for extended time window for IV thrombolysis. So when you look at the original studies, we understand that when you get out beyond four and a half hours, if you just take all-comers, the risk is going to start to outweigh the benefit. But that doesn't mean there's zero benefit or that no one would receive benefit, but it's a question of, well, how do we cherry-pick those patients who may still receive benefit? And there are a few real specifics in the guideline that help us figure that out. One is for patients who have an unknown time of onset, but they're within four and a half hours of symptom discovery. And for those patients, they would suggest that doing a stat MRI and comparing a DWI lesion with the corresponding area flare to determine if you see DWI hyper-intensity and the flare image is nice and normal, that would suggest that stroke is young enough that it may still be appropriate to treat that patient. But we would also say for folks who have salvageable ischemic penumbra, so again, brain at risk that is not core yet, who either awoke with stroke symptoms within nine hours from the midpoint of sleep or, and this is the kicker, are within four and a half to nine hours from last known well. So in other words, they may have been symptomatic already for more than four and a half hours. If those patients have an appropriate ischemic penumbra, it may be reasonable to treat them with IV thrombolysis to improve functional outcomes. Dr. Andy Southerland: Well, that's all for this Neurology Minute. We hope this vibrant conversation will help all those who are out looking to make the best treatment decisions for their patients, both based on established evidence and most recent evidence in our new guidelines.  

In part one of this series, Dr. Andy Southerland talks with Dr. Dan Ackerman about the latest guidelines for managing acute ischemic stroke, emphasizing thrombolytic therapy, imaging techniques, and decision-making regarding treatment in extended time windows. Disclosures can be found at Neurology.org. 

Dr. Andy Southerland and Dr. Layne Dylla discuss the trends in head CT use in US emergency departments from 2007 to 2022, highlighting disparities, regional variations, and the potential role of AI in optimizing imaging decisions.  Show citations:  Dylla L, Krothapalli N, Tu L, et al. Trends in Head CT Use in US Emergency Department Patients From 2007 to 2022: A Nationwide Analysis. Neurology. 2025;105(12):e214347. doi:10.1212/WNL.0000000000214347

Dr. Andy Southerland talks with Dr. Layne Dylla about the trends in head CT use in US emergency departments from 2007 to 2022, highlighting disparities, regional variations, and the potential role of AI in optimizing imaging decisions.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

In this episode, Dr. Andy Southerland reviews the Capitol Hill Report from April 6th, focusing on news related to appropriations and several new bills. Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In part two of the series, Dr. Andy Southerland and Dr. Seemant Chaturvedi break down key takeaways from the OCEANIC‑STROKE trial.  Show citation:  Read more about the OCEANIC-STROKE trial.  Show transcript:  Dr. Andy Southerland:  Hello everyone. This is Andy Southerland from the University of Virginia. For today's Neurology Minute, I've just been speaking with my colleague, Seemant Chaturvedi from the University of Maryland, about exciting trials presented at this year's 2026 International Stroke Conference from the American Heart Association, American Stroke Association. And the one we want to discuss for today's Neurology Minute in brief was the OCEANIC-STROKE trial. This was a very large international trial looking at the use of a novel antithrombotic agent, a Factor XI inhibitor, compared to placebo as an adjunct to our traditional antiplatelet therapies for secondary stroke prevention. And it was received with quite a bit of excitement. So Seemant, tell us in brief, what did we learn from OCEANIC-STROKE? Dr. Seemant Chaturvedi:  One new class of agents, which is being tested are the Factor XIa inhibitors. And this has a unique mechanism of action, and it's believed that it can reduce thrombotic events without causing an increase in bleeding, which would be truly a major breakthrough. And so in OCEANIC-STROKE, over 12,000 patients were enrolled with either stroke or high-risk TIA within 72 hours of the last event. And the trial found that patients who had fairly mild strokes with a median NIH score of two, that when you add the asundexian 50 milligrams per day on top of either dual antiplatelet or single antiplatelet therapy, that there was an improved outcome and reduction in stroke with asundexian. There was a 2.2% absolute reduction in ischemic stroke, 26% in relative terms. Stroke, MI, and vascular death was also reduced with asundexian, as was disabling stroke. An exciting finding was that major bleeding was not increased with asundexian. And so this confirmed the preclinical hypothesis. And so I think this was a significant result in terms of reducing recurrent ischemic stroke without increasing bleeding. And so I think we eagerly await the full publication, and I think it could be applicable to many of the patients that we see in our clinical practice. Dr. Andy Southerland:  So asundexian, folks, you'll hear more about this as the drug hopefully comes on the market and we see the full primary publication of this OCEANIC-STROKE trial, but exciting nonetheless to have a possible new treatment to help us reduce the risk of recurrent stroke for our patients. So Seemant, thanks so much again for joining us for today's Neurology Minute. And I encourage all of our listeners, as always, to listen to the full podcast interview ain The Neurology Podcast. Seemant, thanks for joining us. Dr. Seemant Chaturvedi:  My pleasure.  

In part on of this series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss two trials highlighted at the 2026 International Stroke Conference.  Show citation:  Read more about the CHOICE-2 trial.  Show transcript:  Dr. Andy Southerland: Hello everyone. This is Andy Southerland. And for this week's Neurology Minute, I have just been speaking once again with my colleague, Seemant Chaturvedi, about his impressions from this year's 2026 American Heart Association, American Stroke Association International Stroke Conference. We've discussed a number of the very exciting pivotal trials presented at this year's meeting that occurred just a couple of weeks ago. But for the minute today, we want to just highlight two that were represented as late breaking trials in the world of acute stroke treatment. And the first was OPTION, which was a trial looking at extended window thrombolysis patients between four and a half and 24 hours. And the second was in the use of thrombolysis as an adjunct local treatment in patients receiving thrombectomy. So Seemant, to the best of your ability in our brief snippet today, what were the main highlights from these studies? Dr. Seemant Chaturvedi: In the OPTION trial, 570 patients were enrolled from China, and these were patients in the four and a half to 24 hour window with no evidence of large vessel occlusion. And they had a mismatch present at baseline imaging, median NIH score was seven. And when the tenecteplase was administered in this select group of patients, there was improvement in the excellent outcome of about 44% with tenecteplase and 34% with placebo. And there was a slight increase in hemorrhage of about 3%, but no increase in mortality. The second trial, CHOICE-2, also looked at thrombolysis, but it looked at local intraarterial thrombolysis following thrombectomy. And they enrolled patients with a median NIH score of 15 and the patients were enrolled from Spain and they gave a local TPA versus placebo following successful thrombectomy. And they also reported improved outcomes with about 57.5 having an excellent outcome with intraarterial TPA compared to 43% with placebo. There was slightly increased mortality in the TPA group, but this didn't seem to be explained by intracerebral hemorrhage. And so I think both of these were very intriguing and they add some complexity to acute stroke treatment. And so primary stroke centers and comprehensive stroke centers need to discuss the results with their teams and see if they want to embrace these treatment options. Dr. Andy Southerland: Fantastic, Seemant. So bottom line is thrombolysis is much more than it used to be in that very narrow time window and that very narrow indication. There are now patients who may benefit in that extended time window, and it's also being shown to have benefit in cases in which we get incomplete reperfusion with our traditional mechanical thrombectomy. So take that and run with it. Hopefully we can apply it to our stroke systems of care and help patients. Thank you again, Seemant for being with us on today's Neurology Minute. Seek out the full interview and also the primary publications as well.  

Dr. Andy Southerland talks with Dr. Seemant Chaturvedi about the latest findings from the 2026 International Stroke Conference.  Read more about the CHOICE-2 trial. Read more about the OCEANIC-STROKE trial.  Read more about the FASTEST trial.  Disclosures can be found at Neurology.org.

Dr. Andy Southerland and Dr. Shyam Prabhakaran explain the significance of these guidelines and why they are important.  Show citation:  Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. Published online January 26, 2026. doi:10.1161/STR.0000000000000513  Show transcript:  Dr. Andy Southerland: Hello everyone. This is Andy Southerland from the University of Virginia. And for this week's Neurology Minute, I've just been speaking with my colleague, Shyam Prabhakaran, from the University of Chicago, who was the Chair of the 2026 AHA/ASA guidelines for the early management of patients with Acute Ischemic stroke published in the January 2026 online version of the journal, Stroke. So Shyam, in our brief Neurology Minute today, why don't you just give a plea about why these guidelines are so important? Dr. Shyam Prabhakaran: Thanks, Andy. These guidelines are the first guidelines since 2019, so a lot has happened. So when you look at these guidelines, you'll see a lot of new recommendations. In fact, I think the majority have been revised in some way or another. And I'd point to the actual guideline document, which is in the journal Stroke online January '26, and the print version will be for the March edition of the journal Stroke. In addition to that, I'd say because you want to have interpretability and ease of practice, there are a bunch of derivatives on the AHA website that are very useful. They include case studies, they include figures and workflows that could be really useful for you to have these conversations. And there's even a slide deck that was prepared by our AHA ambassadors. There are these young whippersnappers that did a great job putting together a slide deck for anyone to use. They can use that to have conversations locally or anywhere they want. I encourage people, read the guidelines, but then also use the derivative products that people spent a lot of time on developing. Dr. Andy Southerland: Thank you, Shyam. I think that's a great message from the Chair of the writing group, that when you look at these guidelines, they can seem daunting. But the way you all have provided all these additional resources and analogs for people to interpret it and apply it in their own stroke centers and practice, I think folks definitely will be running out to do that, just to seek out the full guideline, and let's apply all this great new evidence to better care for our patients. So Shyam, thanks again for joining us for this week's Neurology Minute. 

Dr. Andy Southerland talks with Dr. Shyam Prabhakaran about the 2026 AHA/ASA guidelines for the early management of acute ischemic stroke, highlighting key recommendations, the role of advanced imaging, and the importance of thrombolysis and thrombectomy.  Read the related article in the journal Stroke.  Disclosures can be found at Neurology.org. 

In this episode, Dr. Andy Southerland reviews the February 9 Capitol Hill Report, highlighting state-level advocacy efforts. Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy.   

Dr. Andy Southerland and Dr. Dipika Aggarwal discuss her remarkable journey as both a physician and a patient. After overcoming stage four colon cancer, she experienced a life‑altering stroke that reshaped her perspective.  Show transcript: Dr. Andy Southerland: Hello everyone. This is Andy Southerland and for this week's Neurology Minute, I've just been speaking with our colleague, Dipika Aggarwal, who's a clinical assistant professor of neurology at University of Kansas, who's been sharing her story for the Physician's Patient series from Cancer Survivorship and as a stroke survivor. And for the Neurology Minute, we wanted to share an important pearl that Dipika shared with me in her interview about stroke recovery and specifically about mental health outcomes after stroke. So Dipika, please, share with us for the Neurology Minute. Dr. Dipika Aggarwal: So yes, my biggest takeaway point from my own stroke experience was the neuropsychiatric complications that can happen as a risk from stroke. The most important ones being post-stroke depression, post-stroke anxiety. Even if the literature says that they can happen just for 30% of the cases, in reality, I think the incidence is more. But then they can affect quality of life of the stroke survivor, the recovery, and even in some cases can affect their mortality. So I think it is really important for healthcare providers, especially the neurologists, to ask their patients how they are doing mentally or emotionally. I think it is as important as checking their vitals during every visit. It is as important as that, because again, it can affect their recovery. Dr. Andy Southerland: Well, thank you, Dipika. I think it's a good message for all of us in the busyness of our clinics and seeing patients in rapid throughput in and out of the hospital with stroke to make sure that not only in those early days, but also all the way out in the continuum of their recovery, to continue to come back to their mental health recovery. And their personal recovery, as you've articulated, which is so critical to one stroke recovery. And for this and more, I really encourage our listeners, please listen to the entirety of this interview. You will come away with it being a better neurologist for your patients. I promise you that. And I'm truly grateful again to Dipika for joining us for this week's Neurology Minute.

Dr. Andy Southerland talks with Dr. Dipika Aggarwal as she shares her profound journey as both a physician and a patient. After battling stage four colon cancer, she faced a stroke that changed her life.  Disclosures can be found at Neurology.org. 

Start the new year with the January 2026 Recall, featuring five episodes focused on the topic of AI in neurology. The episode begins with Dr. Stacey Clardy talking with Stephen Marche about the evolving topic of natural language processing and its impact on neurology and everyday life. The episode leads into a conversation with Drs. Halley Alexander and Sándor Beniczky discussing the use of AI to accurately interpret routine clinical EEG. The conversation continues with Drs. Trey Bateman and David T. Jones discussing the use of FDG-PET imaging and machine learning to improve diagnostic accuracy. The episode transitions into a discussion between Dr. Andy Southerland and Dr. Adam Rodman regarding the implications of LLMs in clinical reasoning and diagnostics. This month's Recall concludes with Dr. Stacey Clardy reflecting on how AI is shaping multiple aspects of life, including podcasts. Podcast links: What Natural Language Processing Could Mean for Careers in Neurology and Publications Artificial Intelligence Interpretation of EEG FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making Superhuman Performance of a LLM on the Reasoning Tasks of a Physician Podcasting in the Age of AI Article links:  The College Essay Is Dead Automated Interpretation of Clinical Electroencephalograms Using Artificial Intelligence An FDG-PET–Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders Superhuman Performance of a Large Language Model on The Reasoning Tasks of a Physician A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial Disclosures can be found at Neurology.org. 

In part two of this two-part series on this year's World Stroke Congress, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the ATLAS meta-analysis.  Learn more on the World Stroke Congress website. 

In part one of this two-part series on this year's World Stroke Congress, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the TRIDENT trial.  Learn more on the World Stroke Congress website. 

Dr. Andy Southerland talks with Dr. Seemant Chaturvedi about the highlights from the 17th World Stroke Congress.  Learn more on the World Stroke Congress website.  Disclosures can be found at Neurology.org.  

Dr. Andy Southerland and Dr. Amrou Sarraj examine whether general anesthesia (GA) compared with non-GA was associated with better functional outcomes in the SELECT2 trial.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213819 

In this episode, Dr. Andy Southerland discusses the Capitol Hill Report from October 6th, covering the government shutdown and its potential impact on you and your patients.  Stay updated with what's happening on the hill by visiting aan.com/chr.  Take a minute to email your members of Congress and ensure your voice is heard! 

Dr. Andy Southerland talks with Dr. Amrou Sarraj about the importance of understanding anesthesia's impact on patient outcomes, the implications for clinical practice, and future research directions in stroke treatment.  Read the related article in Neurology®.  Disclosures can be found at Neurology.org. 

In this episode, Dr. Andy Southerland discusses the Capitol Hill Report from September 8, providing important updates around BrainPAC. Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In the fourth episode of this series, Dr. Andy Southerland discusses the Capitol Hill Report from August 11th, where AAN members met with their local state representatives to discuss making telehealth flexibilities permanent and reforming prior authorization processes. Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In the third episode of this series, Dr. Andy Southerland discusses the latest Capitol Hill Report, which outlines the 2026 Medicare fee schedule proposal.  Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In the second episode of this series, Dr. Andy Southerland discusses the latest Capitol Hill Report, breaking down what a reconciliation bill is and why it matters.  Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In the final episode of this three-part series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the PINGS-2 Trial, which was presented at the 2025 European Stroke Organization Conference. Show reference:  https://eso-stroke.org/wp-content/uploads/Curtain-Raiser-2-1.pdf 

In part two of this three-part series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the OPTIMISTmain Trial, which was presented at the 2025 European Stroke Organization Conference. Show reference:  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00549-5/abstract 

In part one of this three-part series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the BRIDGE-TNK Trial, which was presented at the 2025 European Stroke Organization Conference. Show reference:  https://www.nejm.org/doi/full/10.1056/NEJMoa2503867   

Dr. Andy Southerland talks with Dr. Seemant Chaturvedi about several studies presented at the 2025 European Stroke Organization Conference (ESOC).  Disclosures can be found at Neurology.org. 

In the first episode of this new series, Dr. Andy Southerland discusses the June updates from the AAN's Capitol Hill Report (CHR). This month's CHR update includes a member story from Dr. José Posas.  Stay updated with what's happening on the hill by visiting aan.com/chr.  Learn how you can get involved with AAN advocacy. 

In part two of this two-part series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss the PRESTIAGE-AF trial. Show references: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00333-2/fulltext 

In part one of this two-part series, Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss two trials that were looking at the use of endovascular therapy for medium vessel occlusion.  Show references: https://www.nejm.org/doi/full/10.1056/NEJMoa2411668 https://www.nejm.org/doi/full/10.1056/NEJMoa2408954  

Dr. Andy Southerland talks with Dr. Seemant Chaturvedi about the latest findings from the International Stroke Conference, focusing on advancements in stroke treatment and recovery. Read more about the ESCAPE-MeVO trial.   Read more about the Distal trial. Read more about the ANGEL-TNK trial. Read more about the PRESTIAGE-AF trial.  Read more about the TRANSPORT2 trial. Disclosures can be found at Neurology.org.

Dr. Andy Southerland and Dr. Adam Rodman discuss the implications of large language models in clinical reasoning and diagnostics. Show reference: https://arxiv.org/abs/2412.10849 

Dr. Andy Southerland talks with Dr. Adam Rodman about the implications of large language models in clinical reasoning and diagnostics. Read the related article on arXiv.  Disclosures can be found at Neurology.org.

Dr. Andy Southerland talks with Dr. Scott Friedenberg about the challenges faced by neurologists in balancing financial productivity with optimal patient care Read the related article in Neurology: Clinical Practice. Disclosures can be found at Neurology.org.

Dr. Andy Southerland and Dr. Scott Friedenberg discuss the significant challenge of financial health within a department or practice, and how it impacts patient and provider satisfaction as well as clinical habits. Show reference: https://www.neurology.org/doi/10.1212/CPJ.0000000000200314 

Dr. Andy Southerland talks with Dr. Cheryl Bushnell about the significance of these guidelines, essential messages for clinicians, lifestyle factors influencing stroke risk, unique considerations for women's health, and the necessity to bridge knowledge gaps in stroke prevention. Read the 2024 Guideline for the Primary Prevention of Stroke. Disclosures can be found at Neurology.org.

In the final part of this two-part series, Dr. Andy Southerland and Dr. Lidia Moura discuss strategies on how clinicians can mitigate bias when using large language models. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497 

In part one of the part-two series, Dr. Andy Southerland and Dr. Lidia Moura discuss the major findings related to large language models (LLMs) for neurologic care. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209497 

Dr. Andy Southerland talks with Dr. Lidia Moura about the implications of large language models (LLMs) for neurologic care. Read the related article in Neurology. Disclosures can be found at Neurology.org.

As part of our "Physician as Patient" series, Dr. Andy Southerland talks with Dr. Eric Seachrist about his experience with multiple sclerosis. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

As part of our "Physician as Patient" series, Dr. Andy Southerland talks with Dr. Eric Seachrist about his experience with multiple sclerosis. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

As part of our "Physician as Patient" series, Dr. Andy Southerland talks with Dr. Eric Seachrist about his experience with multiple sclerosis. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. Disclosures can be found at Neurology.org.

Dr. Andy Southerland and Dr. Seemant Chaturvedi discuss recent trials presented at the European Stroke Organization Conference. Show references:  Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy  Rationale and Design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III) Colchicine for Prevention of Vascular Inflammation in Non-CardioEmbolic Stroke (CONVINCE) Intensive Ambulance-Delivered Blood- Pressure Reduction in Hyperacute Stroke This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

Dr. Andy Southerland talks with Dr. Seemant Chaturvedi about recent trials presented at the European Stroke Organization Conference. Show references:  Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy  Rationale and Design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III) Colchicine for Prevention of Vascular Inflammation in Non-CardioEmbolic Stroke (CONVINCE) Intensive Ambulance-Delivered Blood- Pressure Reduction in Hyperacute Stroke This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. Disclosures can be found at Neurology.org.

Dr. Dan Ackerman and Dr. Andy Southerland discuss the impact of glucose control on the risk of symptomatic intracerebral hemorrhage following thrombolysis for acute ischemic stroke. Show references: https://www.neurology.org/doi/10.1212/WNL.0000000000209323  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. 

Dr. Dan Ackerman talks with Dr. Andy Southerland about the impact of glucose control on the risk of symptomatic intracerebral hemorrhage following thrombolysis for acute ischemic stroke. Read the related article in Neurology.  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. Disclosures can be found at Neurology.org.

Dr. Andy Southerland talks with Dr. Andrea Lendaris about her experience of having Usher syndrome type 2A along with her journey of having acute and chronic health challenges.  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. Disclosures can be found at Neurology.org.